Determinants for successful smoking cessation with bupropion in daily practice

被引:1
作者
Bouvy, ML
Buurma, H
Egberts, ACG
机构
[1] SIR Inst Pharm Practice Res, NL-2331 JE Leiden, Netherlands
[2] Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands
[3] Hosp Pharm Midden Brabant, Tweesteden, Netherlands
[4] St Elizabeth Hosp, Tilburg, Netherlands
来源
PHARMACY WORLD & SCIENCE | 2003年 / 25卷 / 05期
关键词
bupropion; clinical practice; smoking cessation;
D O I
10.1023/A:1025892031198
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: to describe the patterns of use of bupropion in daily clinical practice and factors which determine successful smoking cessation. Methods: Retrospective follow-up study in 36 pharmacies in the Netherlands. Patients who received at least one prescription for bupropion between January and April, 2000 were included. The pharmacists noted several characteristics relating to the patient, use of bupropion and co-medication. Patients were interviewed by telephone about their current and former smoking habits, the success of their smoking cessation and their experiences with bupropion. Main outcome measure: Abstinence rate and factors determining successful abstinence after six months. Results: 322 patients with a least one prescription for bupropion were identified. In 93.5% of patients bupropion was prescribed by the general practitioner. Half of the patients were dispensed 30 or fewer tablets. Pharmacists interviewed 215 (66.8%) patients by telephone. Of these patients 58 (27.0%) still did not smoke six months after the prescription for bupropion. The number of tablets used, lack of co-morbidity, less than two previous attempts to stop smoking and private-insurance were associated with a higher rate of successful abstinence. Conclusion: Most patients do not use bupropion in accordance with the recommended period and did not receive the same degree of additional support provided in clinical trials. Nevertheless 27.0% of patients reported to have stopped smoking six months after the prescription for bupropion. This self-reported abstinence rate is only slightly lower than is reported in literature. This might be partly related to the fact that we did not validate smoking cessation by carbonmonoxide monitoring. Bupropion is not reimbursed in the Netherlands. It is difficult to assess whether patients' self-payment has led to the selection of motivated patients, or has been a barrier to finishing using bupropion.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 50 条
[31]   Bupropion as an aid to smoking cessation:: a review of real-life effectiveness [J].
Holmes, S ;
Zwar, N ;
Jiménez-Ruiz, CA ;
Ryan, PJ ;
Browning, D ;
Bergmann, L ;
Johnston, JA .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (03) :285-291
[32]   Extended treatment with bupropion SR for cigarette smoking cessation [J].
Killen, Joel D. ;
Fortmann, Stephen P. ;
Murphy, Greer M., Jr. ;
Hayward, Chris ;
Arredondo, Christina ;
Cromp, DeAnn ;
Celio, Maria ;
Abe, Laurie ;
Wang, Yun ;
Schatzberg, Alan F. .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 2006, 74 (02) :286-294
[33]   A bupropion smoking cessation clinical trial for cancer patients [J].
Robert A. Schnoll ;
Elisa Martinez ;
Kristina L. Tatum ;
Dorothy M. Weber ;
Natalie Kuzla ;
Marcella Glass ;
John A. Ridge ;
Corey Langer ;
Curtis Miyamoto ;
E. Paul Wileyto ;
Frank Leone .
Cancer Causes & Control, 2010, 21 :811-820
[34]   A bupropion smoking cessation clinical trial for cancer patients [J].
Schnoll, Robert A. ;
Martinez, Elisa ;
Tatum, Kristina L. ;
Weber, Dorothy M. ;
Kuzla, Natalie ;
Glass, Marcella ;
Ridge, John A. ;
Langer, Corey ;
Miyamoto, Curtis ;
Wileyto, E. Paul ;
Leone, Frank .
CANCER CAUSES & CONTROL, 2010, 21 (06) :811-820
[35]   Bupropion SR and contingency management for adolescent smoking cessation [J].
Gray, Kevin M. ;
Carpenter, Matthew J. ;
Baker, Nathaniel L. ;
Hartwell, Karen J. ;
Lewis, A. Lee ;
Hiott, D. Walter ;
Deas, Deborah ;
Upadhyaya, Himanshu P. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2011, 40 (01) :77-86
[36]   DETERMINANTS OF OUTCOME IN SMOKING CESSATION [J].
LENNOX, AS .
BRITISH JOURNAL OF GENERAL PRACTICE, 1992, 42 (359) :247-252
[37]   Statistical analysis of daily smoking status in smoking cessation clinical trials [J].
Li, Yimei ;
Wileyto, E. Paul ;
Heitjan, Daniel F. .
ADDICTION, 2011, 106 (11) :2039-2046
[38]   Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation [J].
Quaak, Marieke ;
van Schayck, Constant P. ;
Postma, Dirkje S. ;
Wagena, Edwin J. ;
van Schooten, Frederik J. .
ADDICTION, 2012, 107 (01) :178-187
[39]   Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation [J].
Clark, Austin ;
Tate, Brendan ;
Urban, Bretton ;
Schroeder, Ryan ;
Gennuso, Sonja ;
Ahmadzadeh, Shahab ;
McGregor, David ;
Girma, Brook ;
Shekoohi, Sahar ;
Kaye, Alan D. .
HEALTH PSYCHOLOGY RESEARCH, 2023, 11
[40]   Use of Sustained-Release Bupropion in Specific Patient Populations for Smoking Cessation [J].
Serena Tonstad .
Drugs, 2002, 62 :37-43